Volume 17 (2020)
Volume 16 (2019)
Volume 15 (2018)
Volume 14 (2017)
Volume 13 (2016)
Volume 12 (2015)
Volume 11 (2014)
Volume 10 (2013)
Volume 9 (2012)
Volume 8 (2011)
Volume 7 (2010)
Volume 6 (2009)
Volume 5 (2008)
Volume 4 (2007)
Volume 3 (2006)
Volume 2 (2005)
Volume 1 (2004)
1. The Reaction of Placental GRP78 Protein with Sera from Women with Multiple Sclerosis

Behrouz Gharesi-Fard; Maryam Zare; Eskandar Kamali-Sarvestani

Volume 14, Issue 4 , Autumn 2017, , Pages 306-315

Abstract
    Background: Multiple Sclerosis (MS) with four different types is one of the well studied autoimmune diseases of the central nervous system. Generally, two-thirds of MS patients are females who are at risk of pregnancy-related complications. Inappropriate responses of mother’s immune system, ...  Read More

2. Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis

Forooz Peiravian; Hamid Rajaian; Afshin Samiei; Nasser Gholijani; Behrouz Gharesi-Fard; Pooneh Mokaram; Abbas Rahimi-Jaberi; Eskandar Kamali Sarvestani

Volume 13, Issue 3 , Summer 2016, , Pages 186-196

Abstract
  Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and cytokines may play a role in the development of MS lesions. Objective: To determine levels of different cytokines in patients with relapsing-remitting MS (RR-MS) compared to healthy controls. Methods: Profiles ...  Read More

3. Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin

Mansour Salehi; Bahram Bagherpour; Vahid Shayghannejad; Farzaneh Mohebi; Rasool Jafari

Volume 13, Issue 2 , Spring 2016, , Pages 141-147

Abstract
  Background: Management of multiple sclerosis (MS) is based on the usage of immunosuppressive and immune-modulating medications. Cytokines play an important role in the pathogenesis of MS. Objective: To evaluate the effects of rapamycin on the concentrations of Th1/Th2/Th17 serum cytokines in patients ...  Read More

4. Interferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis

Keyvan Ghasami; Fardin Faraji; Masoud Fazeli; Ali Ghazavi; Ghasem Mosayebi

Volume 13, Issue 1 , Winter 2016, , Pages 16-26

Abstract
  Background: Statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. Objective: To evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled ...  Read More

5. Immune Rebound: Multiple Sclerosis after Treatment of Cushing’s disease

Mahmood Soveid; Peyman Petramfar

Volume 13, Issue 1 , Winter 2016, , Pages 64-68

Abstract
  High cortisol level in endogenous Cushing’s syndrome suppresses the immune system and after treatment there may be an over activity of immune reaction leading to autoimmune diseases mostly thyroid and rheumatologic disorders. This is the second reported case of multiple sclerosis developing after ...  Read More

6. The Effect of Plasma Exchange on the Expression of FOXP3 and RORC2 in Relapsed Multiple Sclerosis Patients

Azam Jamshidian; Mohammad Kazemi; Vahid Shaygannejad; Mansoor Salehi

Volume 12, Issue 4 , Autumn 2015, , Pages 311-318

Abstract
  Background: Lack of sufficient information on the mechanism of plasma exchange (PE) therapy in multiple sclerosis (MS), has limited this treatment to individual patients with severe relapses who have been refractory to other treatments. This is while PE is used very successfully as a first-line standard ...  Read More

7. Correlation of Midkine Serum Level with Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis

Vahid Shaygannejad; Saeed Montazeri; Azam Jamshidian; Soheil Tahani; Marjan Gharagozloo; Fereshteh Ashtari; Sahar Vesal; Seyed Javad Hasheminia; Leila Dehghani

Volume 11, Issue 2 , Spring 2014, , Pages 134-138

Abstract
  Background: Midkine (MK) is a heparin-binding growth factor with promoting effects in inflammatory responses through enhancing leukocytes migration. Objective: To study the correlation between MK serum levels and concentration of inflammatory cytokines in Multiple Sclerosis (MS) patients. Methods: We ...  Read More

8. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients

Seyed Javad Hasheminia; Sayyed Hamid Zarkesh-Esfahani; Sepideh Tolouei; Vahid Shaygannejad; Hedaiatallah Shirzad; Morteza Hashemzadeh Chaleshtory

Volume 11, Issue 2 , Spring 2014, , Pages 74-83

Abstract
  Background: Multiple sclerosis (MS) is a T cell mediated autoimmune disease with unknown etiology. Appropriate MS therapeutic strategies need thorough understanding of both disease etiology and pathogenesis mechanisms. Ligation of TLR-2 and TLR-4 stimulates the production of several cytokines leading ...  Read More

9. Increased IL-17A but Decreased IL-27 Serum Levels in Patients with Multiple Sclerosis

Zohreh Babaloo; Reza Khajir Yeganeh; Mehdi Farhoodi; Behzad Baradaran; Mohamadreza Bonyadi; Leila Aghebati

Volume 10, Issue 1 , Winter 2013, , Pages 47-54

Abstract
  Background: Effector CD4+ T cell subsets play an important role in Multiple Sclerosis (MS). Interleukin-27 (IL-27) suppresses Th (Th1, Th2 and Th17) cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells (Tr1). Objective: To identify the relative ...  Read More

10. Expression of Chemokine Receptors on Th1/Th2 CD4+ Lymphocytes in Patients with Multiple Sclerosis

Alireza Andalib; Hassan Doulabi; Mohammadreza Najafi; Mehdi Tazhibi

Volume 8, Issue 1 , Winter 2011, , Pages 1-10

Abstract
  Background: Th1 cells preferentially express CXCR3, CCR5 and CCR6, while CCR3 and CCR4 are predominantly expressed by Th2 cell subsets. Multiple Sclerosis (MS) is a Th1 cell-dependant chronic inflammatory disease of the central nervous system, and immunomudolatory cytokines could alter the chemokine ...  Read More

11. Does Mesenchymal Stem Cell Therapy Help Multiple Sclerosis Patients? Report of a Pilot Study

Mandana Mohyeddin Bonab; Sepideh Yazdanbakhsh; Jamshid Lotfi; Kamran Alimoghaddom; Fatemeh Talebian; Farnaz Hooshmand; Ardeshir Ghavamzadeh; Behrouz Nikbin

Volume 4, Issue 1 , Winter 2007, , Pages 50-57

Abstract
  Background: Mesenchymal stem cells (MSCs) with their potential to differentiate into mesodermal and non-mesodermal lineages have several immunomodulatory characteris-tics. These properties make them promising tools in cell and gene therapy. Objective: To evaluate the potential therapeutic applications ...  Read More

12. Investigation of FcγRIIA and FcγRIIIA Polymorphism in Multiple Sclerosis: A Case Control Study

Alireza Nikseresht; Mohammad Ali Azizi; Behrouz Gharesi-Fard; Eskandar Kamali Sarvestani

Volume 3, Issue 3 , Summer 2006, , Pages 136-141

Abstract
  Background: Multiple Sclerosis (MS), the most common demyelinating disease of the CNS, is immunologically mediated in genetically susceptible individuals. Receptors for the Fc fragment of IgG (FcγR) might induce inflammatory responses through linking the humoral and cellular immune responses by ...  Read More